Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry
about
Pharmaceutical policies: effects of policies that determine which drugs are reimbursedPharmaceutical policies: effects on rational drug usePharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesPharmaceutical policies: effects on rational drug useEvaluating drug prices, availability, affordability, and price components: implications for access to drugs in MalaysiaPrices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.Clinical and economic evaluation of surgical treatments for faecal incontinence.International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.Pharmacy utilization and the Medicare Modernization Act.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.Successes, challenges and developments in Australian rheumatology.Drug reimbursement: indicators of inappropriate resource allocation.A decade of growth in public and private pharmaceutical expenditures: the case of Belgium 1990-1999.Impact of the fourth hurdle on the international pharmaceutical industry.US pharmaceutical innovation in an international context.
P2860
Q24187567-E7892D64-D712-4C76-ADD0-5DB9B0AFCB94Q24244044-25EAB8B0-221E-4930-96A1-8E76109DBBA5Q24246148-E3F83B48-867D-4DB1-A589-2A6F54E0AB28Q24248087-8AA8BE55-38E1-48E1-BC50-582A38CFA687Q28469169-C8B15EAA-F8D2-4148-8D73-5368D2C33152Q34092558-D5BB5616-CF57-427C-834B-61C3A75CB904Q34328061-12468EE6-AFA3-4BAA-B6E7-33346491335AQ34715725-A8BA1A9A-7296-4CC8-95E6-B78717088526Q36078786-73D676B2-0E36-41F5-A0A5-AECAC59035B1Q38178581-CE3FF088-FF36-4F62-B766-12D046C12566Q38371949-A549B15D-5CC0-4DC5-AD71-9602EC6C9350Q41879412-667FAFA1-A2B0-49C9-AEDB-6CEBC1C4CA83Q47236274-0BE4C9D4-750D-4963-A60F-DF075C619BBCQ51027981-D5B8F734-0193-452C-A159-6992D9795096Q53175420-F8BDCF2D-6852-4586-ADA3-E77B60C71112
P2860
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Lessons from international exp ...... ture. III: Regulating industry
@ast
Lessons from international exp ...... ture. III: Regulating industry
@en
type
label
Lessons from international exp ...... ture. III: Regulating industry
@ast
Lessons from international exp ...... ture. III: Regulating industry
@en
prefLabel
Lessons from international exp ...... ture. III: Regulating industry
@ast
Lessons from international exp ...... ture. III: Regulating industry
@en
P2093
P2860
P356
P1433
P1476
Lessons from international exp ...... ture. III: Regulating industry
@en
P2093
P2860
P356
10.1136/BMJ.313.7048.33
P407
P577
1996-07-01T00:00:00Z